Journal of Bone and Mineral Metabolism

, Volume 15, Issue 3, pp 153–159 | Cite as

Clinical application of immunoassay for urinary total excretion of deoxypyridinoline in patients with osteoporosis

  • Kiyoshi Nakatsuka
  • Takami Miki
  • Kiichiro Sekiya
  • Hidetaka Kawakami
  • Yoshiko Hirota
  • Masakazu Miura
  • Yasue Obi
  • Yoshiki Nishizawa
  • Hirotoshi Morii
Original Articles


Urinary excretion of pyridinium cross-links is one of the biochemical markers for bone resorption in metabolic bone diseases. Efficacy of immunoassay for deoxypyridinoline (D-pyr) for monitoring effects of antiresorptive therapy was evaluated in 44 women with osteoporosis, including 4 patients with asymptomatic primary hyperparathyroidism. Urinary free forms and protein-bound (conjugated) forms of D-pyr were measured totally by a modified enzyme-liked immunoabsorbent assay (ELISA; PYRILINKS-DTM, Metra Biosystem, Mountain View, CA, USA), which required prehydrolysis of urine samples and adequate acidity adjusted with alkali. There was a close relationship between total excretion of D-pyr measured by reverse-phase high performance liquid chromatography (HPLC) and that measured by ELISA. In 27 patients, the percent change of urinary D-pyr by ELISA following hormone replacement therapy (HRT) was similar to that of urinary total forms of D-pyr using HPLC at the end of the first third, and sixth month. In 8 patients whose series of urine samples were corrected following HRT, the percent change of urinary total excretion of D-pyr by ELISA at the end of the third month was approximately −40%, significantly greater than that of excretion of free forms of D-pyr measured by ELISA (−30%;P<.01). In 16 patients, total urinary D-pyr excretion measured by both methods of HPLC and ELISA decreased by approximately 12% within 4h after a single administration of 20 IU of salmon calcitonin. There were significant differences between percent change of urinary total excretion and that of free forms of D-pyr measured by ELISA (P<.05). We conclude that short-term and subtle change of bone resorption following a single injection of salmon calcitonin, as well as long-term effects of HRT, can be detected by measuring total D-pyr excretion in urine irrespective of assays utilized. A modified assay using ELISA for urinary total D-pyr with an easy procedure provides an informative and cost-beneficial tool in monitoring bone resorption in patients with osteoporosis.

Key words

pyridinium cross-link immunoassay osteoporosis hormone replacement therapy calcitonin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Uebelhart D, Gineyts E, Chapuy M-C, Delmas PD (1990) Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 8:87–96PubMedCrossRefGoogle Scholar
  2. 2.
    Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ (1991) Evaluation of urinary hydroxypyridinium crosslink measurement as resorption markers in metabolic bone diseases. Eur J Clin Invest 21:310–315PubMedGoogle Scholar
  3. 3.
    Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C (1991) Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 6:639–644PubMedGoogle Scholar
  4. 4.
    Ohishi T, Kushida K, Takahashi M, Kawana K, Yagi K, Kawakami K, Horiuchi K, Inoue T (1994) Urinary bone resorption markers in patients with metabolic bone disorders. Bone 15:15–20PubMedCrossRefGoogle Scholar
  5. 5.
    Fujimoto D, Suzuki M, Uchiyama A, Miyamoto S, Inoue T (1983) Analysis of pyridinoline, a crosslinking compound of collagen fibers in human urine. J Biochem (Tokyo) 94:1133–1136Google Scholar
  6. 6.
    Robins SP, Duncan A, Riggs BL (1993) Direct measurement of free hydroxypyridinium crosslinks of collagen in urine as a new marker of bone resorption in osteoporosis. In: Christiansen C, Overgaad K (eds) Osteoporosis. Osteopress Aps, Copenhagen, pp 465–468Google Scholar
  7. 7.
    Seyedin SM, Kung VT, Danloff YN, Hesley RP, Gomez B, Nielsen LA, Rosen HN, Zuk RF (1993) Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 8:635–641PubMedGoogle Scholar
  8. 8.
    Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F (1993) Immunoassay of pyridinoline crosslinks excretion in normal adults and in Paget's disease. J Bone Miner Res 8:643–648PubMedGoogle Scholar
  9. 9.
    Fledelius C, Riis BJ, Overgaad K, Christiansen C (1994) The diagnostic validity of urinary free pyridinoline to identify women at risk of osteoporosis. Calcif Tissue Int 54:381–384PubMedCrossRefGoogle Scholar
  10. 10.
    Kamel S, Brazier M, Oicard C, Boitte F, Samson L, Desmet G, Sebert JL (1994) Urinary excretion of pyridinoline crosslinks measured by immunoassay and HPLC techniques in normal subjects and in elderly patients with vitamin D deficiency. Bone Miner 26:197–208PubMedCrossRefGoogle Scholar
  11. 11.
    Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ (1994) Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643–1649PubMedGoogle Scholar
  12. 12.
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–1700PubMedCrossRefGoogle Scholar
  13. 13.
    Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD (1995) Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10:641–648PubMedCrossRefGoogle Scholar
  14. 14.
    Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedGoogle Scholar
  15. 15.
    Schlemmer A, Hassager C, Jensen SB, Christiansen C (1992) Marked diurnal variation in urinary excretion of pyridinium crosslinks in premenopausal women. J Clin Endocrinol Metab 74:476–480PubMedCrossRefGoogle Scholar
  16. 16.
    Aoshima H, Kushida K, Takahashi M, Ohishi T, Kawana K, Inoue T (1996) Circadian rhythm of the urinary crosslinks pyridinoline and deoxypyridinoline in normal humans and involutional osteoporosis. J Bone Miner Metab 14:83–88CrossRefGoogle Scholar
  17. 17.
    Fujimoto D, Moriguchi T, Ishida T, Hayashi H (1978) The structure of pyridinoline: a collagen crosslinks. Biochem Biophys Res Commun 84:52–57PubMedCrossRefGoogle Scholar
  18. 18.
    Black D, Duncan A, Robins SP (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high performance liquid chromatography. Anal Biochem 169:197–203PubMedCrossRefGoogle Scholar
  19. 19.
    Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, Raisz LG (1994) The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79:366–371PubMedCrossRefGoogle Scholar
  20. 20.
    Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD (1991) Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 72:367–373PubMedCrossRefGoogle Scholar
  21. 21.
    Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R (1993) Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 8: 881–889PubMedGoogle Scholar
  22. 22.
    Nakatsuka K, Miki T, Kawakami H, Nishizawa Y, Morii H (1995) Effects of salmon calcitonin on bone resorption assessed by urinary excretion of pyridinium cross-links in postmenopausal osteoporosis. (in Japanese) Osteoporosis Jpn 3:498–500Google Scholar
  23. 23.
    Nishizawa Y, Hagiwara S, Nakatsuka K, Aratani H, Miki T, Morii H (1995) Efficacy of low dose, intermittent eel calcitonin treatment for oseoporosis. J Bone Miner Metab 13:23–26CrossRefGoogle Scholar
  24. 24.
    Kollerup G, Hermann AP, Brixen K, Lindblad BE, Mosekilde L, Sorensen OH (1994) Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis. Calcif Tissue Int 54:12–15PubMedCrossRefGoogle Scholar
  25. 25.
    Thamsborg G, Jensen JEB, Kollerup G, Hauge EM, Melsen F, Sorensen OH (1996) Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 18:207–212PubMedCrossRefGoogle Scholar
  26. 26.
    Kraenzlin ME, Seibel MJ, Trechsel U, Boerlin V, Azria M, Kraenzlin CA, Haas HG (1996) The effect of intranasal calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 58:216–220PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • Kiyoshi Nakatsuka
    • 1
  • Takami Miki
    • 1
  • Kiichiro Sekiya
    • 1
  • Hidetaka Kawakami
    • 1
  • Yoshiko Hirota
    • 2
  • Masakazu Miura
    • 2
  • Yasue Obi
    • 3
  • Yoshiki Nishizawa
    • 1
  • Hirotoshi Morii
    • 1
  1. 1.Geriatric Medicine and Second Department of Internal MedicineOsaka City University Medical SchoolOsakaJapan
  2. 2.Research and Development DepartmentMitsubishi Kagaku Bio-Clinical LaboratoriesTokyoJapan
  3. 3.Gynecology, Obi ClinicOsakaJapan

Personalised recommendations